Publications
Detailed Information
The Antitumor Effect and Hepatotoxicity of a Hexokinase II Inhibitor 3-Bromopyruvate: In Vivo Investigation of Intraarterial Administration in a Rabbit VX2 Hepatoma Model
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jae, Hwan Jun | - |
dc.contributor.author | Chung, Jin Wook | - |
dc.contributor.author | Park, Hee Sun | - |
dc.contributor.author | Lee, Min Jong | - |
dc.contributor.author | Kim, Hyo-Cheol | - |
dc.contributor.author | Chung, Hesson | - |
dc.contributor.author | Park, Jae Hyung | - |
dc.contributor.author | Yoon, Jung Hwan | - |
dc.contributor.author | Lee, Ki Chang | - |
dc.date.accessioned | 2012-07-02T07:47:31Z | - |
dc.date.available | 2012-07-02T07:47:31Z | - |
dc.date.issued | 2009-12 | - |
dc.identifier.citation | KOREAN JOURNAL OF RADIOLOGY; Vol.10 6; 596-603 | ko_KR |
dc.identifier.issn | 1229-6929 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78118 | - |
dc.description.abstract | Objective: The purpose of this study was to compare the antitumor effect and hepatotoxicity of an intraarterial delivery of low-dose and high-dose 3-bromopyruvate (3-BrPA) and those of a conventional Lipiodol-doxorubicin emulsion in a rabbit VX2 hepatoma model. Materials and Methods: This experiment was approved by the animal care committee at our institution. VX2 carcinoma was implanted in the livers of 36 rabbits. Transcatheter intraarterial administration was performed using low dose 3-BrPA (25 mL in a 1 mM concentration, n = 10), high dose 3-BrPA (25 mL in a 5 mM concentration, n = 10) and Lipiodol-doxorubicin emulsion (1.6 mg doxorubicin/0.4 mL Lipiodol, n = 10), and six rabbits were treated with normal saline alone as a control group. One week later, the proportion of tumor necrosis was calculated based on histopathologic examination. The hepatotoxicity was evaluated by biochemical analysis. The differences between these groups were statistically assessed with using Mann-Whitney U tests and Kruskal-Wallis tests. Results: The tumor necrosis rate was significantly higher in the high dose group (93% +/- 7.6 [mean +/- SD]) than that in the control group (48% +/- 21.7) (p = 0.0002), but the tumor necrosis rate was not significantly higher in the low dose group (62% +/- 20.0) (p = 0.2780). However, the tumor necrosis rate of the high dose group was significantly lower than that of the Lipiodol-doxorubicin treatment group (99% +/- 2.7) (p = 0.0015). The hepatotoxicity observed in the 3-BrPA groups was comparable to that of the Lipiodol-doxorubicin group. Conclusion: Even though intraarterial delivery of 3-BrPA shows a dose-related antitumor effect, single session treatment seems to have limited efficacy when compared with the conventional method. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | KOREAN RADIOLOGICAL SOC | ko_KR |
dc.subject | Hepatocellular carcinoma | ko_KR |
dc.subject | 3-Bromopyruvate | ko_KR |
dc.subject | VX2 carcinoma | ko_KR |
dc.subject | Intraarterial chemotherapy | ko_KR |
dc.subject | Hexokinase II inhibitor | ko_KR |
dc.title | The Antitumor Effect and Hepatotoxicity of a Hexokinase II Inhibitor 3-Bromopyruvate: In Vivo Investigation of Intraarterial Administration in a Rabbit VX2 Hepatoma Model | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 재환준 | - |
dc.contributor.AlternativeAuthor | 정진욱 | - |
dc.contributor.AlternativeAuthor | 박희선 | - |
dc.contributor.AlternativeAuthor | 이민종 | - |
dc.contributor.AlternativeAuthor | 이기창 | - |
dc.contributor.AlternativeAuthor | 김효철 | - |
dc.contributor.AlternativeAuthor | 윤정환 | - |
dc.contributor.AlternativeAuthor | 정혜선 | - |
dc.contributor.AlternativeAuthor | 박재형 | - |
dc.identifier.doi | 10.3348/kjr.2009.10.6.596 | - |
dc.citation.journaltitle | KOREAN JOURNAL OF RADIOLOGY | - |
dc.description.citedreference | Vali M, 2008, J PHARMACOL EXP THER, V327, P32, DOI 10.1124/jpet.108.141093 | - |
dc.description.citedreference | Park HS, 2007, KOREAN J RADIOL, V8, P216 | - |
dc.description.citedreference | Vali M, 2007, J VASC INTERV RADIOL, V18, P95, DOI 10.1016/j.jvir.2006.10.019 | - |
dc.description.citedreference | Shin SW, 2006, ACTA RADIOL, V47, P1036, DOI 10.1080/02841850600977752 | - |
dc.description.citedreference | Gwak GY, 2005, J HEPATOL, V42, P358, DOI 10.1016/j.jhep.2004.11.020 | - |
dc.description.citedreference | Ko YH, 2004, BIOCHEM BIOPH RES CO, V324, P269, DOI 10.1016/j.bbrc.2004.09.047 | - |
dc.description.citedreference | Llovet JM, 2003, LANCET, V362, P1907 | - |
dc.description.citedreference | Yoon CJ, 2003, RADIOLOGY, V229, P126, DOI 10.1148/radio.2291021029 | - |
dc.description.citedreference | Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14 | - |
dc.description.citedreference | Geschwind JFH, 2002, CANCER RES, V62, P3909 | - |
dc.description.citedreference | Ko YH, 2001, CANCER LETT, V173, P83 | - |
dc.description.citedreference | Smith TAD, 2000, BRIT J BIOMED SCI, V57, P170 | - |
dc.description.citedreference | Pedersen PL, 1999, J BIOENERG BIOMEMBR, V31, P291 | - |
dc.description.citedreference | Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68 | - |
dc.description.citedreference | Bosch FX, 1999, SEMIN LIVER DIS, V19, P271 | - |
dc.description.citedreference | Bruix J, 1997, HEPATOLOGY, V25, P259 | - |
dc.description.citedreference | Rempel A, 1996, CANCER RES, V56, P2468 | - |
dc.description.citedreference | Stuart KE, 1996, CANCER, V77, P2217 | - |
dc.description.citedreference | MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918 | - |
dc.description.citedreference | OKADA M, 1995, BRIT J CANCER, V71, P518 | - |
dc.description.citedreference | WATANABE D, 1995, ONCOLOGY, V52, P76 | - |
dc.description.citedreference | REMPEL A, 1994, BBA-GENE STRUCT EXPR, V1219, P660 | - |
dc.description.citedreference | BRUIX J, 1992, J HEPATOL, V15, P350 | - |
dc.description.citedreference | OKUDA K, 1992, HEPATOLOGY, V15, P948 | - |
dc.description.citedreference | SHINOHARA Y, 1991, FEBS LETT, V291, P55 | - |
dc.description.citedreference | KO YH, 1990, ARCH BIOCHEM BIOPHYS, V278, P373 | - |
dc.description.citedreference | BISMUTH H, 1986, WORLD J SURG, V10, P311 | - |
dc.description.citedreference | JOHANSSON T, 1985, BIOCHEM BIOPH RES CO, V133, P608 | - |
dc.description.citedreference | VIITANEN PV, 1984, J BIOL CHEM, V259, P9679 | - |
dc.description.citedreference | BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699 | - |
dc.description.citedreference | PEDERSEN PL, 1978, PROGR EXPT TUMOR RES, V22, P190 | - |
dc.description.citedreference | WEINHOUS.S, 1972, CANCER RES, V32, P2007 | - |
dc.description.tc | 2 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.